Natalizumab (Tysabri) licence extension withdrawn

The manufacturers of natalizumab (Tysabri) have withdrawn their application to extend the European licence to include any people with relapsing remitting MS who didn't have JC virus antibodies. The drug is currently only licensed for people with highly active disease. The evidence available was not yet strong enough to achieve the extension. EMA Natalizumab (Tysabri) - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news